Invivoscribe Begins Commercial Shipments of PrepQuant™ Systems, Enabling High-Sensitivity Sample Preparation for MRD Testing
New automated platform is designed to improve the quality, efficiency, and consistency of DNA extraction and concentration from large-volume blood and plasma samples, supporting downstream assays capable of detecting disease-associated signals at MRD sensitivity levels. SAN DIEGO — Invivoscribe®, a global leader in precision diagnostics and measurable residual disease (MRD) testing, today announced that commercial […]
Financial Post
Published by CurrentWire · First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from Financial Post.
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
How CurrentWire compiled this story
Financial Post (financialpost.com), a Tier B publisher, filed this report on . CurrentWire published this page 23 minutes later, on .
Signal breakdown
CurrentWire ranked this story 61.6 of 100 in the snapshot this page was rendered from.
- Freshness
- 33.6 of 35
- Source authority
- 14 of 20
- Coverage breadth
- 4 of 20
- Geographic relevance
- 3.5 of 10
- Story prominence
- 6.5 of 10
- Velocity
- 0 of 5
Strongest signal: freshness, 33.6 of 35. How each signal is calculated.
Filed under Business · International · News. Topics extracted from this report, with other live CurrentWire stories mentioning each: Commercial Shipments (none), PrepQuant Systems (none), Enabling High-Sensitivity (none), MRD Testing (none).
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.